Sublingual immunotherapy (SLIT) was introduced in the 1980s as a safer option to subcutaneous immunotherapy and in the latest decade achieved significant advances. Its efficacy in allergic rhinitis is supported by a number of meta-analyses. The development of SLIT preparations in tablets to fulfill the requirements of regulatory agencies for quality of allergen extracts made available optimal products for grasspollen-induced allergic rhinitis. Preparations of other allergens based on the same production methods are currently in progress. A notable outcome of SLIT, that is shared with subcutaneous immunotherapy, is the evident cost–effectiveness, showing significant cost savings as early as 3 months from starting the treatment, that become as high as 80% compared with drug treatment in the ensuing years.
Sublingual immunotherapy for allergic rhinitis: where are we now? / Incorvaia, Cristoforo; Mauro, Marina; Ridolo, Erminia. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 7:10(2015), pp. 1105-1110. [10.2217/imt.15.72]
|Appare nelle tipologie:||1.1 Articolo su rivista|